

REMARKS

Applicants have amended the specification to include priority data as required pursuant 37 C.F.R. §1.78.

Applicants respectfully submit that no new matter is added to the present application.

Applicants have attached hereto a marked-up version of the changes made to the specification by the current amendment. The attached marked-up version is labeled "Version with Markings to Show Changes Made – Do Not Enter ". The marked-up version can be found following the signature page of this Amendment.


A favorable response is requested.

Date:

11/26/2001

Pfizer Inc  
Patent Department, 5th Floor  
150 East 42nd Street  
New York, NY 10017-5755  
(212) 733-1038

Respectfully submitted,

  
Adrian G. Looney  
Attorney for Applicants  
Reg. No. 41,406

The following sentence containing the continuing application data for the subject application has been added following the Title of the application on page 1 as follows: “The application claims the benefit of U.S. Provisional Patent Application No. 60/253,513, filed November 28, 2000, which is hereby incorporated by reference in its entirety.”